1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion

Molecular and Cellular Endocrinology

Volumn 413, Issue , 2015, Pages 157-167

  Wijenayaka, Asiri R ^a   Yang, Dongqing ^a   Prideaux, Matthew ^a   Ito, Nobuaki ^a   Kogawa, Masakazu ^a   Anderson, Paul H ^b   Morris, Howard A ^b   Solomon, Lucian B ^a   Loots, Gabriela G ^c,d   Findlay, David M ^a   Atkins, Gerald J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene regulation; Osteocyte; Promoter; Sclerostin; SOST; Vitamin D; Vitamin D response element

Indexed keywords

CALCITRIOL; MESSENGER RNA; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENHANCER REGION; EX VIVO STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; SITE DIRECTED MUTAGENESIS; SOST GENE; TRABECULAR BONE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; VITAMIN D RESPONSIVE ELEMENT; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEINS; CALCITRIOL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; OSTEOCYTES; TRANSCRIPTION, GENETIC; VITAMIN D RESPONSE ELEMENT;

EID: 84938293074     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.06.021     Document Type: Article

References (61)

1. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., O'Loughlin P.D., Morris H.A. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007, 40:1517-1528.
2. Atkins G.J., Findlay D.M. Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int. 2012, 23:2067-2079.
3. Atkins G.J., Kostakis P., Pan B., Farrugia A., Gronthos S., Evdokiou A., Harrison K., Findlay D.M., Zannettino A.C. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Mineral Res. 2003, 18:1088-1098.
4. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., Zelenchuk L., Evdokiou A., Findlay D.M. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Min. Res. 2011, 26:1425-1436.
5. Atkins G.J., Welldon K.J., Holding C.A., Haynes D.R., Howie D.W., Findlay D.M. The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 2009, 30:3672-3681.
6. Atkins G.J., Welldon K.J., Wijenayaka A.R., Bonewald L.F., Findlay D.M. Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am. J. Physiol. Cell. Physiol. 2009, 297:C1358-C1367.
7. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 2002, 39:91-97.
8. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol. 2006, 76:103-127.
9. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., Manolagas S.C., Jilka R.L. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
10. Bonewald L.F. The amazing osteocyte. J Bone Miner Res. 2011, 26:229-238.
11. Brounais B., David E., Chipoy C., Trichet V., Ferré V., Charrier C., Duplomb L., Berreur M., Rédini F., Heymann D., Blanchard F. Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone 2009, 44:830-839.
12. Chen J., Thomas H.F., Sodek J. Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures. Connect. Tissue Res. 1996, 34:41-51.
13. Colussi G., Ganon L., Penco S., De Ferrari M.E., Ravera F., Querques M., Primignani P., Holtzman E.J., Dinour D. Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure. Nephrol. Dial. Transpl. 2013.
14. Dwivedi P.P., Muscat G.E., Bailey P.J., Omdahl J.L., May B.K. Repression of basal transcription by vitamin D receptor: evidence for interaction of unliganded vitamin D receptor with two receptor interaction domains in RIP13delta1. J. Mol. Endocrinol. 1998, 20:327-335.
15. Farrow E.G., Davis S.I., Ward L.M., Summers L.J., Bubbear J.S., Keen R., Stamp T.C., Baker L.R., Bonewald L.F., White K.E. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone 2009, 44:287-294.
16. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., Yu X., Rauch F., Davis S.I., Zhang S., Rios H., Drezner M.K., Quarles L.D., Bonewald L.F., White K.E. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006, 38:1310-1315.
17. Figueres M.L., Linglart A., Bienaime F., Allain-Launay E., Roussey-Kessler G., Ryckewaert A., Kottler M.L., Hourmant M. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am. J. Kidney Dis. 2015, 65:122-126.
18. Findlay, D.M., Atkins, G.J. TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. Adv. Exp. Med. Biol. 691, 337-348.
19. Fisher L.W., Fedarko N.S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect. Tissue Res. 2003, 44(Suppl. 1):33-40.
20. Ito N., Findlay D.M., Anderson P.H., Bonewald L.F., Atkins G.J. Extracellular phosphate modulates the effect of 1alpha,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol. 2013, 136:183-186.
21. Johnson M.L. Unlocking the sost gene. J. Bone Min. Res. 2015, 30:397-399.
22. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
23. Kim S., Yamazaki M., Zella L.A., Shevde N.K., Pike J.W. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol. Cell. Biol. 2006, 26:6469-6486.
24. Kogawa M., Wijenayaka A.R., Ormsby R.T., Thomas G.P., Anderson P.H., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J. Bone Min. Res. 2013, 28:2436-2448.
25. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., Collins J.F., Haussler M.R., Ghishan F.K. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G1036-G1042.
26. Kraichely D.M., MacDonald P.N. Transcriptional activation through the vitamin D receptor in osteoblasts. Front. Biosci. 1998, 3:d821-d833.
27. Kramer I., Loots G.G., Studer A., Keller H., Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Min. Res. 2010, 25:178-189.
28. Lahiri D.K., Ge Y.-W. Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue. Brain Res. Protoc. 2000, 5:257-265.
29. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., Keller H. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Min. Res. 2007, 22:1957-1967.
30. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., Kurahara C., Gao Y., Cao J., Gong J., Asuncion F., Barrero M., Warmington K., Dwyer D., Stolina M., Morony S., Sarosi I., Kostenuik P.J., Lacey D.L., Simonet W.S., Ke H.Z., Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Min. Res. 2008, 23:860-869.
31. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., Li Y., Feng G., Gao X., He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J. Bone Min. Res. 2009, 24:1651-1661.
32. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., Ovcharenko D., Plajzer-Frick I., Rubin E.M. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005, 15:928-935.
33. Matsumoto T., Igarashi C., Takeuchi Y., Harada S., Kikuchi T., Yamato H., Ogata E. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. Bone 1991, 12:27-32.
34. Menon V.B., Moyses R.M., Gomes S.A., de Carvalho A.B., Jorgetti V., Heilberg I.P. Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers. Clin. J. Am. Soc. Nephrol. 2014, 9:1263-1270.
35. Noda M., Vogel R.L., Craig A.M., Prahl J., DeLuca H.F., Denhardt D.T. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc. Natl. Acad. Sci. 1990, 87:9995-9999.
36. O'Brien C.A., Nakashima T., Takayanagi H. Osteocyte control of osteoclastogenesis. Bone 2013, 54:258-263.
37. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Min. Res. 2011, 26:19-26.
38. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J. 2005, 19:1842-1844.
39. Prideaux M., Wijenayaka A.R., Kumarasinghe D.D., Ormsby R.T., Evdokiou A., Findlay D.M., Atkins G.J. SaOS2 osteosarcoma cells as an in vitro model for studying the transition of human osteoblasts to osteocytes. Calcif. Tissue Int. 2014, 95:183-193.
40. Quarles L.D., Yohay D.A., Lever L.W., Caton R., Wenstrup R.J. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J. Bone Mineral Res. 1992, 7:683-692.
41. Rickard D.J., Kazhdan I., Leboy P.S. Importance of 1,25-dihydroxyvitamin D3 and the nonadherent cells of marrow for osteoblast differentiation from rat marrow stromal cells. Bone 1995, 16:671-678.
42. Robling A.G., Bellido T., Turner C.H. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J. Musculoskelet. Neuronal Interact. 2006, 6:354.
43. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., Mantila S.M., Gluhak-Heinrich J., Bellido T.M., Harris S.E., Turner C.H. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J. Biol. Chem. 2008, 283:5866-5875.
44. Silvestrini G., Ballanti P., Leopizzi M., Sebastiani M., Berni S., Di Vito M., Bonucci E. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J. Mol. Histol. 2007, 38:261-269.
45. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62.
46. Spatz J.M., Fields E.E., Yu E.W., Divieti Pajevic P., Bouxsein M.L., Sibonga J.D., Zwart S.R., Smith S.M. Serum sclerostin increases in healthy adult men during bed rest. J. Clin. Endocrinol. Metab. 2012, 97:E1736-E1740.
47. St John H.C., Bishop K.A., Meyer M.B., Benkusky N.A., Leng N., Kendziorski C., Bonewald L.F., Pike J.W. The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone. Mol. Endocrinol. 2014, 28:1150-1165.
48. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., Gardner J.C., Galas D., Schatzman R.C., Beighton P., Papapoulos S., Hamersma H., Brunkow M.E. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 2002, 110:144-152.
49. Stewart K., Walsh S., Screen J., Jefferiss C.M., Chainey J., Jordan G.R., Beresford J.N. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J. Bone Min. Res. 1999, 14:1345-1356.
50. Suda T., Ueno Y., Fujii K., Shinki T. Vitamin D and bone. J. Cell. Biochem. 2003, 88:259-266.
51. Takeshita A., Ozawa Y., Chin W.W. Nuclear receptor coactivators facilitate vitamin D receptor homodimer action on direct repeat hormone response elements. Endocrinology 2000, 141:1281-1284.
52. Tang W.J., Wang L.F., Xu X.Y., Zhou Y., Jin W.F., Wang H.F., Gao J. Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts. Calcif. Tissue Int. 2010, 86:404-410.
53. ten Dijke P., Krause C., de Gorter D.J., Lowik C.W., van Bezooijen R.L. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Jt. Surg. Am. 2008, 90(Suppl. 1):31-35.
54. Teramachi J., Hiruma Y., Ishizuka S., Ishizuka H., Brown J.P., Michou L., Cao H., Galson D.L., Subler M.A., Zhou H., Dempster D.W., Windle J.J., Roodman G.D., Kurihara N. Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease. J. Bone Min. Res. 2013, 28:1489-1500.
55. Thomas G.P., Baker S.U., Eisman J.A., Gardiner E.M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 2001, 170:451-460.
56. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., Fazzalari N.L., Evdokiou A., Atkins G.J. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Min. Res. 2009, 24:1434-1449.
57. Walker E.C., McGregor N.E., Poulton I.J., Solano M., Pompolo S., Fernandes T.J., Constable M.J., Nicholson G.C., Zhang J.G., Nicola N.A., Gillespie M.T., Martin T.J., Sims N.A. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest 2010, 120:582-592.
58. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005, 19:2685-2695.
59. Wein M.N., Spatz J., Nishimori S., Doench J., Root D., Babij P., Nagano K., Baron R., Brooks D., Bouxsein M., Pajevic P.D., Kronenberg H.M. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J. Bone Min. Res. 2015, 30:400-411.
60. Weivoda M.M., Oursler M.J. Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions. Curr. Osteoporos. Rep. 2014, 12:107-114.
61. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011, 6:e25900.